The DOI matches its Crossref record; the references it cites are not checked yet; 22 of the 63 sources its claims cite were checked for support.
SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling
Open accessPublished version of a preprint
Abstract
KRAS is the most frequently mutated human oncogene, and KRAS inhibition has been a longtime goal. Recently, inhibitors were developed that bind KRASG12C-GDP and react with Cys-12 (G12C-Is). Using new affinity reagents to monitor KRASG12C activation and inhibitor engagement, we found that an SHP2 inhibitor (SHP2-I) increases KRAS-GDP occupancy, enhancing G12C-I efficacy. The SHP2-I abrogated RTK feedback signaling and adaptive resistance to G12C-Is in vitro, in xenografts, and in syngeneic KRASG12C-mutant pancreatic ductal adenocarcinoma (PDAC) and non–small cell lung cancer (NSCLC). SHP2-I/G12C-I combination evoked favorable but tumor site–specific changes in the immune microenvironment, decreasing myeloid suppressor cells, increasing CD8+ T cells, and sensitizing tumors to PD-1 blockade. Experiments using cells expressing inhibitor-resistant SHP2 showed that SHP2 inhibition in PDAC cells is required for PDAC regression and remodeling of the immune microenvironment but revealed direct inhibitory effects on tumor angiogenesis and vascularity. Our results demonstrate that SHP2-I/G12C-I combinations confer a substantial survival benefit in PDAC and NSCLC and identify additional potential combination strategies.
Overview
CoChat Summary
TL;DR
SHP2 inhibition with SHP099 increases KRASG12C–GDP occupancy, enhances covalent G12C-inhibitor adduct formation, and blocks adaptive ERK reactivation in KRASG12C PDAC and NSCLC models. The SHP2-I/G12C-I combination causes marked tumor regression, remodels the tumor immune microenvironment, and is potentiated by anti–PD-1.
Key findings
- SHP099/ARS1620 was more effective than either single agent in KRASG12C cell lines and mouse models; in orthotopic KCP PDAC, all SHP099/ARS-treated tumors regressed markedly, and after drug withdrawal median survival was more than doubled versus single-agent–treated mice. In KRASG12C NSCLC GEMMs, SHP099/ARS induced deep responses by 2 wk and complete responses after 4 wk, with all combination-treated mice remaining in remission over an 8-wk treatment period.
- SHP099 accelerated ARS engagement of KRASG12C: ARS adduct formation was complete by 1 h with SHP099/ARS versus only ∼70% engagement with G12C-I alone. SHP099 blocked ARS-evoked KRASG12C-GTP reactivation and ERK reactivation, consistent with SHP2 acting upstream of SOS1/2 to increase KRASG12C-GDP occupancy.
- SHP099/ARS remodeled the TME: in PDAC it increased CD8+ T cells, decreased T reg cells and increased the CD8/T reg ratio, increased B cells, and decreased CD11b+ myeloid cells, with a nearly 50% decrease in g-MDSCs after SHP099/ARS (P = 0.045). It also increased T cell-recruiting chemokines such as CXCL9-11 and CCL5 and decreased myeloid-recruiting chemokines such as CXCL1-5 and CCL9.
- SHP2 inhibition had direct, context-dependent effects on vasculature: SHP099 decreased tumor vascularity in PDAC, including in SHP099-resistant TM/QL tumors, but increased lung tumor–associated blood vessels in NSCLC models. Adding anti–PD-1 to SHP099/ARS produced greater regression than SHP099/ARS or single agent plus anti–PD-1 in PDAC.
Methods
- Cell-based assays used RAS-less MEFs reconstituted with KRAS mutants, human NSCLC and PDAC lines, mouse KCP/KPC PDAC cells, PDX-derived cells, and KRASG12C NSCLC GEMMs; proliferation was measured by PrestoBlue and clonogenic assays, with drug doses of SHP099 10 µM and ARS 10 µM in vitro.
- KRASG12C activity and inhibitor engagement were measured by pull-down with a KRASG12C-GTP–selective monobody (12C/V-MB) and an ARS-adducted KRASG12C–specific Fab (12C-ARS-Ab), plus LC-MS/MS for ARS adducts; pathway output was assessed by immunoblot, qRT-PCR, and RNA-seq.
- In vivo studies used orthotopic KCP PDAC tumors in syngeneic C57BL/6 mice, KRASG12C and KRASG12C;Tp53R270H NSCLC GEMMs monitored by MRI, and xenografts; doses were SHP099 75 mg/kg daily, ARS 200 mg/kg daily, MRTX1257 50 mg/kg daily, and anti–PD-1 200 µg/mouse three times/week. TME analysis used flow cytometry, multiplex IF/IHC, H&E, and Masson trichrome staining.
Limitations
- The paper states that investigators were not blinded to group allocation in xenograft and orthotopic PDAC experiments. It also states that after treatment cessation, both PDAC and NSCLC tumors relapsed, and that whether SHP099’s antiangiogenic/stromal effects reflect altered endothelial or other TME-derived factors versus decreased autocrine signaling by reduced tumor cells remains unclear.
- The paper states that direct effects of SHP2-I on TME cells still require mice expressing drug-resistant SHP2 in specific TME cell types, and such studies were underway. It also notes that ARS is less potent than AMG510 and MRTX1257, and that discrepancies with other studies may reflect tumor location, genotype, histotype, and mouse strain.
- Evident from the text: the main efficacy data are preclinical, using cell lines and mouse models rather than human clinical trials; several mechanistic conclusions rely on drug-resistant PTPN11 mutants and KO/reconstitution systems, and some supporting data are described as not shown.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures







![Figure 5. ARS/SHP099 combination provokes an antitumor immune program in syngeneic PDAC model. (A) Pie charts showing %CD45+ (immune) cells and %CD45- (cancer plus stromal) cells in KCP tumors after 12 d of treatment, as in Fig. 4. (B) Frequencies of infiltrating CD3+ T cells, CD19+ B cells, and CD11b+ myeloid cells. (C) Frequencies of infiltrating CD8+ T cells and respective subpopulations. (D) Frequencies of infiltrating CD4+ T cells and respective subpopulations. (E) Ratio of infiltrating CD8+ T cells to FOXP3+ regulatory CD4+ T cells. (F) Frequencies of infiltrating MDSCs. Data were verified in at least two independent experiments for each subset. (G) Multiplex IF/IHC analysis of KCP tumors, stained with the indicated markers and quantified (n = 3 per each group). Scale bar, 100 µm. For B–G, tumors were analyzed at day 12 after the indicated treatments. CTRL, control. (H) Pie charts showing immune cell (CD45+) composition (top) and tumor volume (bottom) in SQ versus orthotopic (ORTHO) KCP tumors, treated with vehicle (VEH) or ARS + SHP099 (COMBO) for 10 d (n = 3–4/group). Note the greater response of SQ tumors. (I and J) CXCL (I) and CCL (J) chemokine expression in KCP tumors after 3 d of treatment, as assessed by RNA-seq (colors are log10 of raw counts averages and log2FC [left], n = 3 per group [right]). Data represent mean ± SD; *, P < 0.05; **, P < 0.01; ***, P < 0.001; one-way ANOVA with Tukey’s multiple comparison test.](/paper-figures/0cedd547147142fc9da95fc3d283eee4/shp2-inhibition-diminishes-krasg12c-cycling-and-promotes-tumor-microenvironment-figure-5.jpg)






Verification
Claims the paper makes
10 Valid · 2 Not valid · 18 Not checked · 195 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Allosteric SHP2-Is (e.g., SHP099) reduce the activation of KRAS mutants with residual GTPase activity (“cycling mutants”), most notably KRASG12C and, to a lesser extent, KRASG12D and KRASG12V (hereafter G12C, G12D, and G12V) in cancer cell lines and reconstituted “RAS-less” MEFs (Ahmed et al., 2019; Fedele et al., 2018; Hao et al., 2019; Mainardi et al., 2018; Nichols et al., 2018).”
§ SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling > Results > SHP2 inhibition enhances KRASG12C inhibitor effects in PDAC and NSCLC cell lines
What the sources say
- Partly supportedcites Ahmed et al., 2019 sourceExperimental — accuracy not yet measured
The Results section reports that SHP099 suppressed RAS activity in G12-mutant tumor cell lines, including G12C lines, and the Discussion notes variable sensitivity among G12C lines. The passages do not establish the claimed lesser effects on G12D and G12V or report experiments in reconstituted RAS-less MEFs; the other G12 mutants named here are G12A and G12S. Page numbers were not available in our copy. (LLM, conf=0.87)
- Partly supportedcites Fedele et al., 2018 sourceExperimental — accuracy not yet measured
The Results and Discussion report that SHP099 decreased KRAS(G12C)-GTP in MIAPaCa-2 cancer cells and prevented its increase in KRAS(G12C)-reconstituted RAS-less MEFs. For G12D and G12V, the Discussion reports decreased downstream p-ERK in reconstituted MEFs, related to residual GTPase activity, but does not report a direct reduction in activation of those KRAS mutants or establish that effect in cancer cell lines. Page numbers are not available in our copy. (LLM, conf=0.85)
- Not checked yetcites Hao et al., 2019 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
None of the sources cited for this claim have been checked yet.
In the paper
“Some oncogenic mutants, notably KRASG12C (G12C) and, to a lesser extent, KRASG12D (G12D), retain significant intrinsic GTPase activity.”
§ SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling > Introduction
What the sources say
- Could not verifycites Bandaru et al., 2017 sourceExperimental — accuracy not yet measured
The Results and discussion section on G12V discusses reduced intrinsic GTP hydrolysis for Ras-G12V, not KRASG12C or KRASG12D. Searches for G12C and G12D found no passage reporting their intrinsic GTPase activity or comparing the two, so our copy does not establish the attributed claim. (LLM, conf=0.74)
- Could not verifycites Gremer et al., 2011 sourceExperimental — accuracy not yet measured
The Results section on GTP hydrolysis (page unavailable) reports measurements for germline KRAS mutants and compares them with oncogenic G12V, but does not report intrinsic GTPase activity for G12C or G12D. Searches for G12C and G12D found no passage establishing their activity or the claimed difference between them. (LLM, conf=0.75)
- Not checked yetcites Hunter et al., 2015 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recent reports (and our unpublished observations; see Results) show that KRASG12C mutant cancer cell lines treated with G12C-Is also develop adaptive resistance (Hallin et al., 2020; Lou et al., 2019; Misale et al., 2019; Ryan et al., 2020; Xue et al., 2020).”
§ SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling > Introduction
What the sources say
- Partly supportedcites Hallin et al., 2020 sourceExperimental — accuracy not yet measured
Hallin et al. (2020) do document adaptive, feedback-mediated escape from KRASG12C inhibition: the Abstract reports that profiling in 'sensitive and partially resistant non-clinical models' identified 'KRAS nucleotide cycling and pathways that induce feedback reactivation and/or bypass KRAS dependence', and the Discussion links recovery of ERK signaling despite continued treatment to transient or submaximal MRTX849 response. However, the temporal reactivation/rebound experiments underlying 'develop adaptive resistance' were performed in mouse xenograft tumors on repeat dosing (Results, 'Temporal Effects of MRTX849 on KRAS-Dependent Signaling and Feedback Pathways ... Following Repeat Dosing in Xenograft Models'), not in cultured cell lines; the in vitro cell-line data show only partial/incomplete pERK inhibition and submaximal responses in lines such as KYSE-410 and SW1573 (Results, 'MRTX849 is a Potent and Selective Inhibitor ... In Vitro'), i.e. heterogeneous intrinsic sensitivity rather than an acquired adaptive-resistance phenotype in cell lines. The Discussion also stresses that no co-occurring aberration predicted response or resistance in the cell line panel. So the cell-line setting of the citing claim is not what this source establishes. (LLM, conf=0.72)
- Partly supportedcites Lou et al., 2019 sourceExperimental — accuracy not yet measured
Our copy of Lou et al. (2019) works in KRASG12C lines (H358, MIA PaCa-2) treated with the G12C inhibitor ARS-1620 and shows that driver inhibition leaves residual, bypass-supportable growth signals — the Introduction states it is 'likely that, upon direct pharmacological inhibition of KRASG12C, KRASG12C-dependent cancer cells will engage previously dispensable genes and pathways to maintain survival and proliferation,' and the Results/Discussion describe collateral dependencies (RTK/SOS1 inputs, PI3K, CCND1–CDK4) that were 'incompletely suppressed by driver oncogene inhibition' and 'may also promote resistance to direct KRAS inhibitors.' The part the source does not support is the claim as an observed outcome: the paper reports no experiment in which KRASG12C mutant cell lines actually develop adaptive resistance during G12C-inhibitor treatment (searched: adaptive resistance, rebound, drug tolerance); its 'resistance' data are genetic perturbation (sgRNA knockdown) resistance indices in short 12-day CRISPRi screens, and the resistance mechanism is framed as a hypothesis/anticipation rather than a demonstrated finding. (LLM, conf=0.72)
- Not checked yetcites Misale et al., 2019 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recently, several groups, including ours, provided strong evidence that SHP2 acts upstream of SOS1/SOS2 to regulate exchange; consequently, SHP2-Is abrogate adaptive resistance to BRAF or MEK inhibitors (Ahmed et al., 2019; Fedele et al., 2018; Hao et al., 2019; Mainardi et al., 2018; Nichols et al., 2018).”
§ SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling > Introduction
What the sources say
- Partly supportedcites Ahmed et al., 2019 sourceExperimental — accuracy not yet measured
The Discussion reports that combined SHP2 and ERK-signaling inhibition overcomes adaptive resistance to RAF and MEK inhibitors in a defined subset of ERK-dependent tumors. The Results also identify tumor lines whose rebound signaling was insensitive to added SHP2 inhibition, so the claim is too broad without that qualification. (LLM, conf=0.88)
- Partly supportedcites Fedele et al., 2018 sourceExperimental — accuracy not yet measured
The Results section ('SHP099 impedes MEK inhibitor-induced reactivation') reports that SHP099 blocks the adaptive response to MEK inhibitors. For BRAF inhibitors, the Discussion cites earlier work showing an effect of SHP2 depletion, but cautions that the SHP2 inhibitor used in that work has off-target effects. This paper therefore supports the MEK-inhibitor part more clearly than the BRAF-inhibitor part. (LLM, conf=0.86)
- Not checked yetcites Hao et al., 2019 source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recently, several groups, including ours, provided strong evidence that SHP2 acts upstream of SOS1/SOS2 to regulate exchange; consequently, SHP2-Is abrogate adaptive resistance to BRAF or MEK inhibitors (Ahmed et al., 2019; Fedele et al., 2018; Hao et al., 2019; Mainardi et al., 2018; Nichols et al., 2018).”
§ SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling > Introduction
What the sources say
- Partly supportedcites Ahmed et al., 2019 sourceExperimental — accuracy not yet measured
The Discussion says SHP2 can recruit a GRB2/SOS complex to promote RAS activation and discusses SHP2-dependent GEF (SOS) recruitment in relation to nucleotide exchange. It does not distinguish SOS1 from SOS2 or establish the role of both individually, so the isoform-specific part of the claim is not supported by our copy. (LLM, conf=0.82)
- Supportedcites Fedele et al., 2018 source
The Results section states that SHP2 is required for RAS exchange, most likely upstream of SOS1/2. The Discussion further says the authors' findings show that SHP2 acts upstream of SOS. Page numbers are not provided in our copy. (LLM, conf=0.94)
- Not checked yetcites Hao et al., 2019 source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
131 more claims · 5 with their cited sources checked
Create a free account to see all 225 claims and to verify the 41 references still open.
- It may state two separate claims as one. 83
- Probably not a substantial claim. 10
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SHP2 allosteric inhibition can significantly enhance the inhibition of multiple components in RTK signaling, including EGFR, BRAF, MEK1/2, and oncogenic KRAS [72].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [72]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TNO155, a small-molecular SHP2 inhibitor, has demonstrated efficacy when combined with KRAS G12C inhibitors in various preclinical models [72, 89, 90].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [72]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the studies by Fedele et al.50 in syngeneic orthotopic and subcutaneous KRASG12C-mutant tumours revealed depletion of myeloid-derived suppressor cells (MDSCs) and enrichment of cytotoxic T cells in the TME, which was associated with increased sensitivity to PD-1 blockade.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [50]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accordingly, KRASG12Ci plus SHP2 inhibitor (SHP2i; for example TNO155) or EGFR antagonist (EGFRi; for example cetuximab18) combination approaches are now being clinically tested13,16,19,20, with evidence of improved clinical response20–22.”
From Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance (2024) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the initial enthusiasm has been somewhat tempered by work suggesting that acquired resistance may constrain the inhibitors’ efficacy, which indicates that combination therapies may be needed11–14.”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [13]
Experimental — accuracy not yet measured
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling > Results > ARS/SHP099 is also efficacious in KRASG12C NSCLC
“SHP099/ARS reversed these increases (Fig. S5, D and E).”
§ SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling > Results > ARS/SHP099 is also efficacious in KRASG12C NSCLC
“| m-MDSCs | m-MDSCs | m-MDSCs | m-MDSCs | m-MDSCs | m-MDSCs | | SHP2-I | ↑ | ↑ | ↓ | NS | ND | | G12C-I | NS | ↑ | NS | ND | ND | | COMBO | NS | ↑ | NS | ND | ND |”
Citations
The citation lists are queued
They are fetched later and appear here then.
References 88 · Cited by 265
Metadata
- Authors
- Fedele, C., Li, S., Teng, K. W., Foster, C. J. R., Peng, D., Ran, H., Mita, P., Geer, M. J., Hattori, T., Koide, A., Wang, Y., Tang, K. H., Leinwand, J., Wang, W., Diskin, B., Deng, J., Chen, T., Dolgalev, I., Ozerdem, U., Miller, G., Koide, S., Wong, K.-K., & Neel, B. G.
- Affiliations
- NYU Langone Health (US)
- Department of Pathology, New York University School of Medicine, NYU Langone Health, New York, NY 5
- Corresponding author
- Fedele, Carmine
- Wong, Kwok-Kin
- ORCID
- Fedele, Carmine
- Li, Shuai
- Teng, Kai Wen
- Foster, Connor J.R.
- Peng, David
- Ran, Hao
- Mita, Paolo
- Geer, Mitchell J.
- Hattori, Takamitsu
- Koide, Akiko
- Wang, Yubao
- Tang, Kwan Ho
- Leinwand, Joshua
- Wang, Wei
- Diskin, Brian
- Deng, Jiehui
- Chen, Ting
- Dolgalev, Igor
- Ozerdem, Ugur
- Miller, George
- Koide, Shohei
- Wong, Kwok-Kin
- Neel, Benjamin G.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2020-10-08
- Volume
- 218
- Issue
- 1
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC7549316
- OpenAlex
- W3092384396
- Semantic Scholar
- fdfa0584d17c0156026ad1f91de77834ef524a1f
- Cited by
- 265
- References
- 88
- Citations by year
- 2026: 34 · 2025: 41 · 2024: 59 · 2023: 41 · 2022: 53 · 2021: 37
- FWCI
- 10.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (P30CA016087, CA49152, CA219670, CA194864, P30 CA016087)
- Mirati Therapeutics
- American Cancer Society (132652-PF-18-180-01-TBE)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- SHP2 inhibition, KRAS G12C, KRAS inhibitors, adaptive resistance, pancreatic ductal adenocarcinoma, non-small cell lung cancer, tumor microenvironment, myeloid-derived suppressor cells, CD8+ T cells, anti-PD-1 therapy, tumor angiogenesis, combination therapy
- MeSH terms
- Animals, Carcinoma, Non-Small-Cell Lung, Enzyme Inhibitors, Lung Neoplasms, Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Mice, Knockout, Amino Acid Substitution, Mutation, Missense, Carcinoma, Pancreatic Ductal, Mice, Protein Tyrosine Phosphatase, Non-Receptor Type 11, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling. https://app.cochat.ai/papers/10.1084/jem.20201414
- The paper
- Fedele, C., Li, S., Teng, K. W., Foster, C. J. R., Peng, D., Ran, H., Mita, P., Geer, M. J., Hattori, T., Koide, A., Wang, Y., Tang, K. H., Leinwand, J., Wang, W., Diskin, B., Deng, J., Chen, T., Dolgalev, I., Ozerdem, U., . . . Neel, B. G. (2021). SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20201414
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.